LIGOCYTE PHARMACEUTICALS, INC.

Company Information
Address LIGOCYTE PHARMACEUTICALS, INC.
2155 Analysis Drive
BOZEMAN, MT, 59718 0683


Information

DUNS:

# of Employees: N/A


Ownership Information

HUBZone Owned: N

Socially and Economically Disadvantaged: N

Woman Owned: N



Award Charts




Award Listing

  1. Anthrax Vaccine Formulations Combining PA/Spore Epitopes

    Amount: $728,648.00

    DESCRIPTION (provided by applicant): Pulmonary anthrax, a rare but extremely severe form of anthrax, is initiated by phagocytosis of Bacillus anthracis spores by alveolar macrophages (AMs). The curre ...

    SBIRPhase I2004Department of Health and Human Services
  2. TUBERCLE BACILLI BINDING TO HOST CELLS: VACCINE DESIGN

    Amount: $205,728.00

    Three million people die each year from tuberculosis (TB) in spite of the use of the existing anti-mycobacterial antibiotics and the BCG vaccine. Clearly, a better vaccine and better ways to treat TB ...

    STTRPhase I2002Department of Health and Human Services
  3. GROUP B STREPTOCOCCAL PEPTIDE MIMETIC VACCINE

    Amount: $580,839.00

    Group B streptococcus (GBS) causes invasive infections of newborns, pregnant women and adults with underlying medical conditions, such as diabetes or cancer. Despite antibiotic treatment, estimated ca ...

    SBIRPhase I2002Department of Health and Human Services
  4. N/A

    Amount: $0.00

    N/A

    SBIRPhase I2000Department of Health and Human Services
  5. N/A

    Amount: $1,294,354.00

    N/A

    SBIRPhase II2000Department of Health and Human Services
  6. RATIONAL DESIGN OF ADHESION BLOCKING ANTIINFLAMMATORIES

    Amount: $100,000.00

    N/A

    SBIRPhase I1998Department of Health and Human Services
  7. FOOD TEST FOR VEROTOXIN E COLI TO PREVENT INFECTIONS

    Amount: $747,372.00

    N/A

    SBIRPhase II1998Department of Health and Human Services
  8. FOOD TEST FOR VEROTOXIN E COLI TO PREVENT INFECTIONS

    Amount: $76,274.00

    N/A

    SBIRPhase I1996Department of Health and Human Services
  9. Preclinical Development of LIGO-069-136, An Anti-Inflammatory Pulmonary Therapeut

    Amount: $4,089,750.00

    DESCRIPTION (provided by applicant): The LIGO-069-136 Phase II renewal project is a critical path research and development plan designed to qualify an anti-inflammatory monoclonal antibody product for ...

    SBIRPhase IIDepartment of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government